medigraphic.com
ISSN 1561-2988 (Print)

2013, Number 3

<< Back Next >>

Rev Cubana Farm 2013; 47 (3)

Pharmacist counseling for patients with mood disorders

de Souza RV, Alves MR, Tavares VG, Fernandes MR, Radighieri RR, Moreira MLA

Language: Spanish
References: 32
Page: 353-362
PDF size: 96.19 Kb.


ABSTRACT

Introduction: pharmaceutical care is the direct interaction of the pharmacist and the user in order to achieve rational drug therapy and to obtain defined measurable results aimed at improving the life quality of the patient. Depression is considered one of the ten main causes of disability worldwide since it restricts the physical, social and personal functioning of the individual. However, few people having these health problems receive proper treatment and directions about their disease and therapy.
Objective: to evaluate the pharmaceutical care service through counseling on the effectiveness of and adherence to drug therapy.
Methods: nineteen patients were selected, aged 15 to 82 years and with mood disorders. They were all seen at the Psychosocial and Outpatient Care Center of UNIFENAS in Brazil. They were visited at home to give instructions to them about their disease, adverse reactions, and drug interactions, length of treatment and importance of adherence to therapy. Beck depression inventory and Morisky´s test were used to evaluate adherence to treatment before and after the pharmacist counseling.
Results: most of patients were Catholic women, who had been under study for up to 9 years. When comparing the results of the application of the Beck depression inventory before and after the pharmacist counseling, there was observed an statistically significant difference ((p= 0.0354), with a reduction of roughly 6 point in Beck´s score (24,22 for 18). The adherence to treatment rate increased since the number of patients who showed high rate of adherence to therapy rose from 21.06 % to 42.10 %.
Conclusions: the results suggest that the pharmacist counseling could be a useful method to achieve better outcomes in adherence to and effectiveness of treatment.


REFERENCES

  1. World Health Organization. The Global burden of disease. 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/

  2. Peluso ETP, Blay SL. Percepção da depressão pela população da cidade de São Paulo. Rev Saúde Pública. 2008;42:41-8.

  3. Fleck MPA, Lafer B, Sougey EB, Del Porto JA, Brasil MA, Juruena MF. Diretrizes da Associação Médica brasileira para o tratamento da depressão. Rev Bras Psiquiatr. 2003;25(2):114-22.

  4. Marques LAM, Galduróz JCF, Noto AR. Pharmaceutical care to patients treated with antidepressants. Rev Calid Asist. 2012;27(1):55-64.

  5. Fridman GA, Filinger EJ. Atención farmacéutica en pacientes ambulatorios con trastornos psiquiátricos. Lat Am J Pharm. 2003;22 (4):351-4.

  6. Silva EV, Naves JOS, Vidal J. O papel do farmacêutico comunitário no aconselhamento ao paciente. Boletim Farmacoterapêutica. 2008;4-5:1-3.

  7. Morisky DE. Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence. Medical Care. 1986;24:67-74.

  8. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin Pl. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-44.

  9. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh G. An Inventory for Measuring Depression. Arch Gen Psychiatr. 1961;4:53-63.

  10. Dunn G, Sham P, Hand D. Statistics and the Nature of Depression Psychol Med. 1993;23:871-89.

  11. Gotlib IH. Depression and General Psychopathology in University Students. J Abnorm Psychol. 1984;93:19-30.

  12. Oliver JM, Simmons ME. Depression as measured by the DSM-III and Beck Depression Inventory in an Unselected Adult Population. J Consult Clin Psychol. 1984;52:892-8.

  13. Tanaka-Matsuni J, Kameoka VA. Reliabilities and Concurrent Validities of Popular Self-Report Measures of Depression, Anxiety and Social Desirability. J Consul Clin Psychol. 1986;54:328-33.

  14. Louks J, Hayne C, Smith J. Replicated Factor Structure of the Beck Depression Inventory. J Nerv Mental Dis. 1989;177:473-9.

  15. Beck AT, Stee RA, Garpin MG. Psychometric Properties of the Beck Depression Inventory Twenty-Five Years of Evaluation. Clin Psychol Rev. 1988;8:77-100.

  16. Galarza EGV. Estudio y Seguimiento Farmacoterapéutico en pacientes con depresión en consulta externa del Hospital Provincial Docente Ambato. Riobamba-Equador: Escuela Superior Politécnica de Chimborazo, Facultad de Ciencias, Escuela de Bioquímica y Farmacia; 2009.

  17. Adler DA, Bungay KM, Wilson IB, Pei Y, Supran S, Peckham E, Cynn DJ, Rogers WH. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. Gen Hosp Psychiatry. 2004;26:199-209.

  18. Andrade LHSG, De Viana MC, Silveira CM. Epidemiologia dos transtornos psiquiátricos na mulher. Rev Psiquiatr Clín. 2006;33:43-54.

  19. Weissman MM, Bland RC, Canino GJ. Cross-national epidemiologic of major depression and bipolar disorder. JAMA. 1996;276:293-9.

  20. Scalco ZM. Tratamento de idosos com depressão usando tricíclicos, IMAO e outros antidepressivos. Rev Bras Psiquiatr. 2002;24:55.

  21. Auchewski L. Avaliação da orientação médica sobre os efeitos colaterais de benzodiazepínicos. Rev Bras Psiquiatr. 2004;26:24.

  22. Fleck MP, Berlim MT, Lafer B, Sougey EB, Del Porto JA, Brasil MA, Juruena MF, Hetem LA. Revisão das diretrizes da Associação Médica Brasileira para o tratamento da depressão (Versão integral). Rev Bras Psiquiatr. 2009;31:S7-S17.

  23. Al-Saffar N, Abdulkareem A, Abdulhakeem A, Salah AQ, Heba M. Depressed patients' preferences for education about medications by pharmacists in Kuwait. Patient Educ Couns. 2008;72:94-101.

  24. Black E, Murphy AL, Gardner DM. Community pharmacist services for people with mental illnesses: preferences, satisfaction, and stigma. Psychiatr Serv. 2009;60:1123-7.

  25. Cates ME, Burton AR, Woolley TW. Attitudes of pharmacists toward mental illness and providing pharmaceutical care to the mentally ill. Ann Pharmacother. 2005;39(9):1450-5.

  26. Phokeo V, Sproule B, Raman-Wilms L. Community Pharmacists' Attitudes Toward and Professional Interactions with Users of Psychiatric Medication. Psychiatr Serv. 2004;55(12):1434-6.

  27. Scheerder G, De Coster I, Van Audenhove C. Pharmacists' Role in Depression Care: A Survey of Attitudes, Current Practices, and Barriers. Psychiatr Serv. 2008;59(10):1155-60.

  28. Aaltonen SE, Laine NP, Volmer D, Gharat MS, Ruta Muceniece R, Vitola A, et al. Barriers to medication counselling for people with mental health disorders: a six country study. Pharm Pract. 2010;8(2):122-31.

  29. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2(6):757-64.

  30. Gabarró MB. El cumplimiento terapéutico. Pharm Care Esp. 1999;1:97-106.

  31. Demyttenaere K. Compliance and acceptance in antidepressant treatment. Int J Psychiatr ClinlPract. 2001;5:29-35.

  32. Balon R. Managing compliance. Psychiatric Times [Internet]. 2002 [Acceso: 2012 Mar 3];19(5):1-2. Available from: http://www.psychiatrictimes.com/display/article/10168/48206




2020     |     www.medigraphic.com